Recent Updates
Recently added Catalysts
COLL Positive Sentiment

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Key Takeaway: Collegium Pharmaceutical, Inc. will report its third quarter 2025 financial results on November 6, 2025, before market opening. Following the release, a live conference call and webcast will occur at 8:00 a.m. ET. The company aims to enhance its portfolio, focusing on responsible pain management and ADHD treatments.
Price reaction · baseline $35.71 (2025-10-22 close) · hit pre-market · clean, no other COLL news in the window
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collegium is committed to improving lives with its biopharmaceutical products.
  • The company has a strong portfolio in pain management and neuropsychiatry.
  • Jornay PM is highlighted as a leading growth driver for the company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
0.4%
average across 3 past catalysts
Lead asset
Evolocumab
Phase 3 · Sars-CoV-2 Infection

Full Press Release Details

STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) --Collegium Pharmaceutical, Inc.(Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website:www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website atwww.collegiumpharma.com.

Investor Contacts:Ian KarpHead of Investor Relationsir@collegiumpharma.com

Frequently Asked Questions

When will Collegium report its Q3 2025 financial results?

Collegium will report its Q3 2025 financial results on November 6, 2025.

What time is the Collegium earnings call scheduled?

The earnings call is scheduled for 8:00 a.m. ET on November 6, 2025.

How can I access the Collegium conference call?

You can access the conference call by dialing (877) 407-8037 for U.S. callers.

Where can I find the webcast of the earnings call?

The webcast will be available on Collegium's website in the Investors section.

Last updated: Oct 23, 2025